Skip to main content
AmigoFish

PsychRounds: The Psychiatry Podcast

Dr. Tanner Hewitt, Dr. Larry Wang and Dr. Bradley MillerAudio

Format:
Podcast
New episodes:
Every two weeks
Typical length:
about 20 minutes
Latest episode:
Not rated yet
CosmosOpen at the sourceReport a problemIs this your show? Get a badge

About this show

Welcome to Psych Rounds, the podcast tailored for psychiatry residents and students. Join us, three psychiatric resident physicians, as we delve into quick insights, interviews, and practical tips essential for educational practice. Subscribe for a straightforward yet informal approach to psychiatric knowledge.

Contact us: psychroundspodcast@gmail.com Instagram: https://www.instagram.com/psychrounds/

Covers: psychiatry, medical education, psychopharmacology, mental health, depression treatment, ADHD medication, antipsychotic drugs, addiction medicine, dsm diagnosis, clinical trials

Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.

Recently on this show

Summary of recent episodes, drawn from the publisher's feed.

This podcast, made by psychiatry residents, is aimed at psychiatry trainees and students and offers quick insights, interviews and practical teaching tips. Recent episodes cover a validity-based diagnostic hierarchy, a new long-acting olanzapine injection, GLP-1 drugs in psychiatry, the STAR*D depression trial, and dogs and mental health.

Report a problem with this summary

Cosmos

Similar in subject

See the full Cosmos

Similar shows

See all Health shows

Explore more

Episodes

  • Landmark Studies: STEP-BD

    · 22 min

    Welcome back! Our journal club continues... today we are going over the Systematic Treatment Enhancement Program for Bipolar Disorder, more commonly known as "STEP-BD". References: https://www.nejm.org/doi/full/10.1056/NEJMoa064135 (https://www.nejm.org/doi/full/10.1056/NEJMoa064135?utm_source=openevidence) https://pubmed.ncbi.nlm.nih.gov/12788248 https://onlinelibrary.wiley.com/doi/10.1111/j.1399-5618.2009.00715.x https://pubmed.ncbi.nlm.nih.gov/16449474/ https://pubmed.ncbi.nlm.nih.gov/20409444/

    Not rated yet
  • A Validity-Based Diagnostic Hierarchy with Dr. Mark Ruffalo and Dr. Ronald Pies

    · 53 min

    Today, we welcome back a former guest, Dr. Mark Ruffalo, and joining him is his colleague and co-author, Dr. Ronald Pies. We will be discussing their recently published article, The Need For A Validity-Based Hierarchy In DSM-6. Article: https://pubmed.ncbi.nlm.nih.gov/42908074/ Dr. Ruffalo Website: https://www.drruffalo.com/ Dr. Pies Psychiatric Times Profile: https://www.psychiatrictimes.com/authors/ronald-w-pies-md

    Not rated yet
  • A New Long-Acting Injectable: Olanzapine (Zyprexa) Weltruza

    · 24 min

    Today, we're covering the recent FDA approval of a new Olanzapine long-acting injectable - Weltruza. References: https://pubmed.ncbi.nlm.nih.gov/41632432/ https://pubmed.ncbi.nlm.nih.gov/42198294/ https://www.tevapharm.com/news-and-media/latest-news/new-long-term-safety-data-from-the-completed-phase-3-solaris-trial-support-the-potential-of-olanzapine-la/

    Not rated yet
  • Pharmacogenetic Testing in Psychiatry

    · 22 min

    Welcome back, everyone! We’re back after PRITE, and today we’re discussing pharmacogenetic testing.

    Not rated yet
  • GLP-1 Agonists (Ozempic, Wegovy) in Psychiatry

    · 32 min

    Today, we will discuss GLP-1's and the emerging use of this class of medications in psychiatry. Sources: https://pubmed.ncbi.nlm.nih.gov/42247271/ https://pmc.ncbi.nlm.nih.gov/articles/PMC11441540/ https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2838205 (https://jamanetwork.com/journals/jamapsychiatry/article-abstract/2838205?utm_source=openevidence&utm_medium=referral) https://pubmed.ncbi.nlm.nih.gov/42070571 https://pubmed.ncbi.nlm.nih.gov/41806782/

    Not rated yet
  • Landmark Studies: The STAR*D Trial

    · 28 min

    We resume our landmark studies series looking at the pivotal study in Major Depressive Disorder (MDD), The STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial. References: https://pubmed.ncbi.nlm.nih.gov/12778843/ https://pubmed.ncbi.nlm.nih.gov/19880458/ https://jamanetwork.com/journals/jamapsychiatry/fullarticle/482026 (https://jamanetwork.com/journals/jamapsychiatry/fullarticle/482026?utm_source=openevidence&utm_medium=referral) https://pubmed.ncbi.nlm.nih.gov/15061154/ https://pubmed.ncbi.nlm.nih.gov/20370962/ https://pubmed.ncbi.nlm.nih.gov/37491091/

    Not rated yet
  • Dogs in Mental Health with Dr. Nancy Gee: A Biopsychosocial Approach

    · 54 min

    We have a special guest today to talk about one of our favorite topics... dogs! Most people might intuitively say that they feel like their dogs improve their mental health, but today, we look at the science with the leading expert on the subject. Dr. Nancy Gee Profile: https://medschool.vcu.edu/about/portfolio/details/geen2/ References: Dogs Supporting Human Health and Well-Being: A Biopsychosocial Approach: https://pubmed.ncbi.nlm.nih.gov/33860004/ Randomized Controlled Trials: https://pmc.ncbi.nlm.nih.gov/articles/PMC12728353/, https://pmc.ncbi.nlm.nih.gov/articles/PMC11714157/

    Not rated yet
  • Centanafadine (Simtriyo): A New Medication for ADHD

    · 28 min

    Welcome back! Today, we are talking about Simtriyo, which has generated a lot of media attention recently given a newly minted FDA approval for ADHD. References https://pmc.ncbi.nlm.nih.gov/articles/PMC12314114/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12379780/ https://pubmed.ncbi.nlm.nih.gov/31776871/ https://pubmed.ncbi.nlm.nih.gov/40619095/ https://pubmed.ncbi.nlm.nih.gov/28731336/ https://pmc.ncbi.nlm.nih.gov/articles/PMC9426730/

    Not rated yet
  • Landmark Studies: The CATIE Trial

    · 21 min

    Today we're starting a new type of series - looking at some of the most seminal studies in psychiatry. We're going to start with the CATIE Trial, which was published in 2005. References: https://www.nejm.org/doi/full/10.1056/NEJMoa051688 (https://www.nejm.org/doi/full/10.1056/NEJMoa051688?utm_source=openevidence) https://pubmed.ncbi.nlm.nih.gov/19594194/ https://pubmed.ncbi.nlm.nih.gov/17924259/ https://pubmed.ncbi.nlm.nih.gov/17286522/ https://www.nejm.org/doi/full/10.1056/NEJMoa061240 (https://www.nejm.org/doi/full/10.1056/NEJMoa061240?utm_source=openevidence) https://jamanetwork.com/journals/jamapsychiatry/fullarticle/209844

    Not rated yet
  • The Rising Use of Recreational Kratom

    · 21 min

    Apologies for our little hiatus - a couple of us had cross-country moves in June. But we're back! Today we have an episode on the rising use of recreational Kratom and pertinent tidbits to know from a psychiatry standpoint. References: - https://pmc.ncbi.nlm.nih.gov/articles/PMC8924421/ - https://www.ncbi.nlm.nih.gov/books/NBK585120/ - https://pmc.ncbi.nlm.nih.gov/articles/PMC10846393/ - https://pmc.ncbi.nlm.nih.gov/articles/PMC10177737/

    Not rated yet
  • Modafinil (Provigil)

    · 19 min

    Welcome back! Today, we are looking at Modafinil and it's nuanced use in psychiatry. References: - Provigil (modafinil) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA, Inc. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfdadocs/label/2015/020717s037s038lbl.pdf - Schwartz JR. Modafinil in the treatment of excessive sleepiness. Drug Des Devel Ther. 2009;2:71–85. - Kaplan S, Goehring EL Jr, Engel T, et al. Cardiovascular outcomes associated with modafinil in patients with obstructive sleep apnea. Pharmacoepidemiol Drug Saf. 2018;27(11):1182–1190. doi:10.1002/pds.4642 - Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738. doi:10.1016/S2215-0366(18)30269-4 - Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101–1107. doi:10.4088/JCP.13r08560 - Bahji A, Mesbah-Oskui L. Comparative efficacy and safety of stimulant-type medications for depression: a systematic review and network meta-analysis. J Affect Disord. 2021;292:416–423. doi:10.1016/j.jad.2021.05.119 - Nunez NA, Singh B, Jorgensen A, et al. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: a meta-analysis of randomized controlled trials. Bipolar Disord. 2020;22(2):109–120. doi:10.1111/bdi.12859

    Not rated yet
  • Naltrexone

    · 16 min

    Welcome Back! Today we are discussing the medication Naltrexone and its uses in psychiatry. References: - https://www.ncbi.nlm.nih.gov/books/NBK534811/ - https://pubmed.ncbi.nlm.nih.gov/24825644/ - https://pubmed.ncbi.nlm.nih.gov/26798982/ - https://www.nejm.org/doi/full/10.1056/NEJMct0801733 (https://www.nejm.org/doi/full/10.1056/NEJMct0801733?utm_source=openevidence) - https://pubmed.ncbi.nlm.nih.gov/26798982/

    Not rated yet
  • Placebo Effect and Response in Psychiatry

    · 22 min

    Welcome back! Today, we will be discussing the placebo effect. References: https://pubmed.ncbi.nlm.nih.gov/16503356/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003660/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8556377/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714297/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6694178/#:~:text=Several%20mechanisms%20have%20been%20described,the%20treatment%20provider%20(24))/ https://www.psychiatrypodcast.com/psychiatry-psychotherapy-podcast/2018/11/19/understanding-placebo

    Not rated yet
  • Amantadine (Symmetrel)

    · 17 min

    Welcome back! Today we are talking all about Amantadine, and it's uses in psychiatry.

    Not rated yet
  • VMAT2 Inhibitors: Valbenazine (Ingrezza) and Deutetrabenazine (Austedo)

    · 17 min

    Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo). References: https://pubmed.ncbi.nlm.nih.gov/41626799/ https://www.ncbi.nlm.nih.gov/books/NBK548187/ https://pubmed.ncbi.nlm.nih.gov/41626799/

    Not rated yet
  • A DSM Conversation with Dr. Allen Frances

    · 55 min

    We are back with another special guest episode! Please welcome Dr. Allen Frances, who was intricately involved in the formation of both the DSM III and DSM IV, the latter of which he served as chair. https://x.com/AllenFrancesMD https://www.amazon.com/stores/author/B001HO76FU https://www.psychiatrictimes.com/authors/allen-frances-md

    Not rated yet
  • Topiramate (Topamax)

    · 15 min

    Welcome back! Today we will be doing a brief episode on Topiramate [Topamax], and its clinical uses in psychiatry. References: - https://pubmed.ncbi.nlm.nih.gov/21438989/ - https://pubmed.ncbi.nlm.nih.gov/18774432/ - https://pubmed.ncbi.nlm.nih.gov/25899459/ - https://pmc.ncbi.nlm.nih.gov/articles/PMC1088011/ - https://pmc.ncbi.nlm.nih.gov/articles/PMC2671954/ - https://pubmed.ncbi.nlm.nih.gov/38706338/ - https://pubmed.ncbi.nlm.nih.gov/20207521/

    Not rated yet
  • What Makes Something a Psychiatric Illness? Featuring Dr. Mark Ruffalo, MSW, DPsa

    · 54 min

    Welcome back, today we are discussing a deceptively difficult topic: What makes something a psychiatric illness? We are joined by our guest Dr. Mark Ruffalo. He is a psychotherapist in private practice in Tampa, FL, and who also serves as Assistant Professor of Psychiatry at the University of Central Florida College of Medicine as well an Adjunct Assistant Professor of Psychiatry at Tufts University School of Medicine. Dr. Ruffalo's Website: https://www.drruffalo.com/ Dr. Ruffalo's LinkedIn: https://www.linkedin.com/in/mark-l-ruffalo-71929063 PRISM: https://www.psychiatrictimes.com/view/use-of-the-prism-diagnostic-instrument-in-clinical-practice PRISM Writing Contest: https://www.psychiatrictimes.com/view/prism-writing-contest-more-on-this-new-diagnostic-tool-from-mark-ruffalo-msw-dpsa

    Not rated yet
  • Lorazepam (Ativan)

    · 14 min

    Welcome back! Today we are at the highly prescribed and popular benzodiazepine Lorazepam, also known as Ativan. We look at its uses in psychiatry, especially catatonia. But despite anecdotal efficacy, does the evidence hold up? References: - https://www.ncbi.nlm.nih.gov/books/NBK532890/ - https://pubmed.ncbi.nlm.nih.gov/36805317/ - https://pubmed.ncbi.nlm.nih.gov/6120058/ - https://pubmed.ncbi.nlm.nih.gov/10229064/ - https://psychopharmacologyinstitute.com/section/catatonia-diagnosis-the-lorazepam-challenge-2911-5899/

    Not rated yet
  • The Vitamin Series: Iron Deficiency in Psychiatry

    · 25 min

    Welcome back! Today we are embarking into the first of hopefully several episodes on the importance of vitamins and minerals in mental health. We will specifically be looking at the role of iron deficiency in psychiatry and do an overview on some of the recent research that's been published. References: - https://www.ncbi.nlm.nih.gov/books/NBK557376/ - https://www.sciencedirect.com/science/article/pii/S0268960X25000827#bb0165 - https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2823909 - https://www.sciencedirect.com/science/article/pii/S1389945717315599 - https://pubmed.ncbi.nlm.nih.gov/40841680/ - https://pubmed.ncbi.nlm.nih.gov/1677067/ - https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00463-7/fulltext - https://pmc.ncbi.nlm.nih.gov/articles/PMC6139360/

    Not rated yet